Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-12-06 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
独立董事关于公司有关事项所发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding the nomination of a candidate for the company's board of directors. It references compliance with company law and stock exchange rules, and it is a formal statement of approval for a board nomination. There is no financial data, no report of financial results, no audit information, and no announcement of voting results. The content is about board/management information, specifically about the nomination and approval of an independent director candidate. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a regulatory filing. Hence, the classification is MANG with high confidence.
2021-12-06 Chinese
关于召开2021年第三次临时股东大会补充通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2021 third extraordinary general meeting of shareholders of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes information about the meeting date, location, agenda items, voting procedures, and proxy forms. The content focuses on the logistics and formalities of the shareholders meeting, including proposals to be voted on, such as changes in registered capital, transfer of subsidiary shares, and appointment of independent directors. There is no financial data, earnings information, or management discussion of financial results. The document is not a report itself but an official notice and supplementary announcement related to a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and proposals to be voted on, and includes proxy forms and voting instructions, it aligns best with Proxy Solicitation & Information Statement (PSI).
2021-12-06 Chinese
关于2021年第三次临时股东大会增加临时提案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the addition of a temporary proposal to the agenda of the company's 2021 third extraordinary general meeting of shareholders. It discusses procedural details about the shareholder meeting, the proposal to nominate an independent director, and references prior notices and disclosures related to the meeting. There are no financial statements, earnings data, or detailed report content. The document is a formal announcement about shareholder meeting agenda changes, not the meeting materials themselves or voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is about adding a proposal to the meeting agenda and not the solicitation of votes or the voting results, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the shareholder meeting agenda change that does not fit other categories precisely. The document length is short (1372 characters), and it is an announcement rather than a report or transcript.
2021-12-06 Chinese
第五届董事会第二十三次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the resignation of an independent director and the nomination of a new independent director candidate. It details the board meeting resolutions, the qualifications of the new candidate, and compliance with relevant laws and stock exchange rules. There is no financial data or report content, but rather a formal disclosure about board composition changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-12-06 Chinese
独立董事提名人声明
Regulatory Filings Classification · 95% confidence The document is a formal public statement from the board of Shenzhen Xinlitai Pharmaceutical Co., Ltd. nominating an independent director candidate. It details the nominee's qualifications, compliance with various regulatory requirements, and declarations regarding independence and eligibility. There is no financial data, no mention of financial results, no discussion of management changes beyond the nomination, and no indication of a report or meeting materials. This document is a regulatory announcement related to board nominations and compliance with listing rules, but it is not a management change announcement per se (which would be more about appointments or resignations). It is also not a proxy solicitation or voting results announcement. Given the nature of the content—declarations and compliance statements related to an independent director nomination—it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-06 Chinese
关于独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director (ZHANG MENG) from the company's board. It details the resignation, the reasons, and the impact on the board composition. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content is clearly about a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on this management change, confirming the classification.
2021-12-06 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.